Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Javle, Milind; Roychowdhury, Sameek; Kelley, Robin Kate; Sadeghi, Saeed; Macarulla, Teresa; Weiss, Karl Heinz; Waldschmidt, Dirk-Thomas; Goyal, Lipika; Borbath, Ivan; El-Khoueiry, Anthony; Borad, Mitesh J.; Yong, Wei Peng; Philip, Philip A.; Bitzer, Michael; Tanasanvimon, Surbpong; Li, Ai; Pande, Amit; Soifer, Harris S.; Shepherd, Stacie Peacock; Moran, Susan; Zhu, Andrew X.; Bekaii-Saab, Tanios S.; Abou-Alfa, Ghassan K.

Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study

Author:

Javle, Milind; Roychowdhury, Sameek; Kelley, Robin Kate; Sadeghi, Saeed; Macarulla, Teresa; Weiss, Karl Heinz; Waldschmidt, Dirk-Thomas; Goyal, Lipika; Borbath, Ivan; El-Khoueiry, Anthony; Borad, Mitesh J.; Yong, Wei Peng; Philip, Philip A.; Bitzer, Michael; Tanasanvimon, Surbpong; Li, Ai; Pande, Amit; Soifer, Harris S.; Shepherd, Stacie Peacock; Moran, Susan; Zhu, Andrew X.; Bekaii-Saab, Tanios S.; Abou-Alfa, Ghassan K.

Tübinger Autor(en):

Bitzer, Michael

Published in:

Lancet Gastroenterology & Hepatology (2021), Bd. 6, H. 10, S. 803-815

Verlagsangabe:

Elsevier Inc

Language:

English

Full text:

https://doi.org/10.1016/S2468-1253(21)00196-5

ISSN:

2468-1253